US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OneStream, Inc.

23.98

+0.15000.63%

Post-market: 23.980.0001+0.00%19:25 EDT

Volume:10.63M

Turnover:254.83M

Market Cap:4.56B

PE:-85.64

High:24.04

Open:23.80

Low:23.77

Close:23.83

52wk High:29.66

52wk Low:16.51

Shares:190.00M

Float Shares:84.67M

Volume Ratio:9.22

T/O Rate:12.55%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2800

EPS(LYR):-0.2800

ROE:-12.41%

ROA:-6.41%

PB:9.03

PE(LYR):-85.64

Loading ...

Overview Company News Filings

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Why Is Arcellx Stock Surging Today?

Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

OneStream (OS): Assessing Valuation After Strategic Leadership Changes and AI-Focused Growth Plans

Simply Wall St.

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

OneStream Director Jonathan D. Mariner Reports Sale of Common Shares

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

OneStream Names Scott Leshinski President and Appoints John Kinzer Interim CFO

Onestream Inc - John Kinzer to Join Onestream as Interim CFO January 1, 2026

THOMSON REUTERS

Onestream Inc - CFO BILL Koefoed to Depart December 31, 2025

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OS/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"OneStream, Inc.","latestPrice":23.98,"timestamp":1774641600000,"preClose":23.83,"halted":0,"volume":10627005,"hourTrading":{"tag":"盘后","latestPrice":23.9801,"preClose":23.98,"latestTime":"19:25 EDT","volume":129371,"amount":3101317.0003,"timestamp":1774653924406,"change":0.0001,"changeRate":0.000004,"amplitude":0.000446},"delay":0,"changeRate":0.00629458665547638,"floatShares":84669400,"shares":190000000,"eps":-0.28,"marketStatus":"Market Closed","change":0.15,"latestTime":"03-27 16:00:00 EDT","open":23.8,"high":24.035,"low":23.77,"amount":254834910.398685,"amplitude":0.01112,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.28,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":23.83,"preHourTrading":{"tag":"盘前","latestPrice":23.76,"preClose":23.83,"latestTime":"06:39 EDT","volume":393,"amount":9344.780331,"timestamp":1774607953342,"change":-0.07,"changeRate":-0.002937,"amplitude":0.001259},"postHourTrading":{"tag":"盘后","latestPrice":23.9801,"preClose":23.98,"latestTime":"19:25 EDT","volume":129371,"amount":3101317.0003,"timestamp":1774653924406,"change":0.0001,"changeRate":0.000004,"amplitude":0.000446},"volumeRatio":9.223979,"impliedVol":0.1765,"impliedVolPercentile":0.0996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":84669400,"roa":"-6.41%","roe":"-12.41%","lyrEps":-0.28,"volumeRatio":9.223979,"shares":190000000,"dividePrice":0,"high":24.035,"amplitude":0.01112,"preClose":23.83,"low":23.77,"week52Low":16.51,"pbRate":"9.03","psRate":"7.57","week52High":29.66,"institutionHeld":0,"latestPrice":23.98,"eps":-0.28,"divideRate":0,"volume":10627005,"delay":0,"ttmEps":-0.28,"open":23.8,"prevYearClose":18.38,"prevWeekClose":23.77,"prevMonthClose":23.59,"prevQuarterClose":18.38,"fiveDayClose":23.77,"twentyDayClose":23.59,"sixtyDayClose":18.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-04-02","symbol":"OS","reason":null,"defaultRemindTime":1775136600000,"announcedDate":"2026-03-27","type":"delisting","dateTimestamp":1775102400000},{"market":"US","date":"2026-02-26","symbol":"OS","fiscalQuarterEnding":"2025/12","expectedEps":0.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"post","actualEps":0.12},{"market":"US","date":"2025-11-06","symbol":"OS","fiscalQuarterEnding":"2025/09","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":0.08},{"market":"US","date":"2025-08-07","symbol":"OS","fiscalQuarterEnding":"2025/06","expectedEps":0.01,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":0.05},{"market":"US","date":"2025-05-08","symbol":"OS","fiscalQuarterEnding":"2025/03","expectedEps":-0.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":0.04}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.05,"hold":0.9,"sell":0.05,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.9,"analysts":20,"updateTime":1772251200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2026-03-27","current":-85.642857,"percent":0.165049,"low":-1655.61542,"twenty":-89.449174,"median":-26.639308,"eighty":-17.110068,"high":-12.620803,"avg":-209.091161,"sd":455.110442,"marketCap":4531148320},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-05-02","current":-17.960471,"twenty":-1411.604376,"median":-27.370467,"eighty":-18.532156,"marketCap":3883071858},{"date":"2025-05-09","current":-18.233962,"twenty":-1408.19776,"median":-27.329108,"eighty":-18.405555,"marketCap":4289685457},{"date":"2025-05-16","current":-21.240398,"twenty":-1401.871187,"median":-27.223413,"eighty":-18.515128,"marketCap":4996973579},{"date":"2025-05-23","current":-21.307828,"twenty":-1386.882076,"median":-27.071763,"eighty":-18.645114,"marketCap":5012836988},{"date":"2025-05-30","current":-20.970679,"twenty":-1384.546111,"median":-26.979854,"eighty":-18.713226,"marketCap":4933519947},{"date":"2025-06-06","current":-21.779837,"twenty":-1366.053052,"median":-26.837395,"eighty":-18.714534,"marketCap":5123880845},{"date":"2025-06-13","current":-21.083062,"twenty":-1357.293182,"median":-26.745487,"eighty":-18.76981,"marketCap":4959958960},{"date":"2025-06-20","current":-21.397734,"twenty":-630.517125,"median":-26.722672,"eighty":-18.799724,"marketCap":5033988198},{"date":"2025-06-27","current":-20.715944,"twenty":-446.043303,"median":-26.635196,"eighty":-18.835877,"marketCap":4873591516},{"date":"2025-07-03","current":-19.974216,"twenty":-441.960461,"median":-26.551186,"eighty":-18.852455,"marketCap":4699094026},{"date":"2025-07-11","current":-19.329886,"twenty":-438.862005,"median":-26.400131,"eighty":-18.891318,"marketCap":4547510347},{"date":"2025-07-18","current":-18.603142,"twenty":-435.145985,"median":-26.322706,"eighty":-18.792246,"marketCap":4376538059},{"date":"2025-07-25","current":-18.767971,"twenty":-431.217662,"median":-26.184843,"eighty":-18.769074,"marketCap":4415315279},{"date":"2025-08-01","current":-17.868906,"twenty":-429.132806,"median":-25.973452,"eighty":-18.719624,"marketCap":4203803170},{"date":"2025-08-08","current":-16.647677,"twenty":-428.119335,"median":-25.013004,"eighty":-18.618108,"marketCap":3916499222},{"date":"2025-08-15","current":-15.000942,"twenty":-427.308558,"median":-24.227183,"eighty":-18.552195,"marketCap":3687831610},{"date":"2025-08-22","current":-15.038842,"twenty":-426.26613,"median":-22.921489,"eighty":-18.339199,"marketCap":3697149022},{"date":"2025-08-29","current":-15.031262,"twenty":-424.84727,"median":-21.776091,"eighty":-18.209869,"marketCap":3695285539},{"date":"2025-09-05","current":-14.902401,"twenty":-422.588676,"median":-21.667454,"eighty":-17.977035,"marketCap":3663606339},{"date":"2025-09-12","current":-14.629519,"twenty":-419.519305,"median":-21.457672,"eighty":-17.846429,"marketCap":3596520974},{"date":"2025-09-19","current":-14.72806,"twenty":-417.405493,"median":-21.307828,"eighty":-17.519829,"marketCap":3620746244},{"date":"2025-09-26","current":-14.77354,"twenty":-413.351607,"median":-21.281605,"eighty":-17.355901,"marketCap":3631927139},{"date":"2025-10-03","current":-14.030694,"twenty":-406.749563,"median":-21.240398,"eighty":-17.207371,"marketCap":3449305866},{"date":"2025-10-10","current":-14.117865,"twenty":-400.610822,"median":-21.169222,"eighty":-16.756085,"marketCap":3470735914},{"date":"2025-10-17","current":-12.620803,"twenty":-398.265359,"median":-21.090554,"eighty":-16.357703,"marketCap":3102698146},{"date":"2025-10-24","current":-13.666851,"twenty":-397.193975,"median":-21.023124,"eighty":-16.016618,"marketCap":3359858713},{"date":"2025-10-31","current":-13.735072,"twenty":-395.977809,"median":-20.970679,"eighty":-15.832245,"marketCap":3376630054},{"date":"2025-11-07","current":-14.462758,"twenty":-395.456595,"median":-20.749659,"eighty":-15.429973,"marketCap":3555524361},{"date":"2025-11-14","current":-49.128605,"twenty":-394.616862,"median":-20.970679,"eighty":-15.543674,"marketCap":4065244662},{"date":"2025-11-21","current":-44.083947,"twenty":-393.313827,"median":-21.023124,"eighty":-15.695275,"marketCap":3647814359},{"date":"2025-11-28","current":-47.333434,"twenty":-390.910451,"median":-21.086808,"eighty":-15.767745,"marketCap":3916699644},{"date":"2025-12-05","current":-42.56146,"twenty":-321.664361,"median":-21.157984,"eighty":-15.81759,"marketCap":3521833141},{"date":"2025-12-12","current":-41.038973,"twenty":-53.555179,"median":-21.221667,"eighty":-15.87621,"marketCap":3395851924},{"date":"2025-12-19","current":-41.311658,"twenty":-51.928163,"median":-21.277859,"eighty":-15.887608,"marketCap":3418415724},{"date":"2025-12-26","current":-42.788697,"twenty":-51.673657,"median":-21.292844,"eighty":-15.933201,"marketCap":3540636308},{"date":"2026-01-02","current":-41.766131,"twenty":-50.564742,"median":-21.307828,"eighty":-15.991821,"marketCap":3456022057},{"date":"2026-01-09","current":-53.627894,"twenty":-52.309921,"median":-21.525102,"eighty":-16.02676,"marketCap":4437547364},{"date":"2026-01-16","current":-54.099771,"twenty":-53.976775,"median":-21.667454,"eighty":-16.063653,"marketCap":4476593727},{"date":"2026-01-23","current":-54.168483,"twenty":-54.099771,"median":-21.779837,"eighty":-16.096034,"marketCap":4482279494},{"date":"2026-01-30","current":-54.145579,"twenty":-54.131837,"median":-23.997411,"eighty":-16.222689,"marketCap":4480384238},{"date":"2026-02-06","current":-53.481357,"twenty":-54.122675,"median":-24.240542,"eighty":-16.388421,"marketCap":4425421826},{"date":"2026-02-13","current":-53.98525,"twenty":-54.108933,"median":-25.376044,"eighty":-16.452502,"marketCap":4467117449},{"date":"2026-02-20","current":-54.053962,"twenty":-54.099771,"median":-25.973452,"eighty":-16.49986,"marketCap":4472803216},{"date":"2026-02-27","current":-88.924297,"twenty":-54.099771,"median":-26.212415,"eighty":-16.600021,"marketCap":4472803216},{"date":"2026-03-06","current":-89.781839,"twenty":-54.145579,"median":-26.3312,"eighty":-16.756085,"marketCap":4515936743},{"date":"2026-03-13","current":-89.214796,"twenty":-54.237196,"median":-26.460569,"eighty":-16.928396,"marketCap":4487415038},{"date":"2026-03-20","current":-89.895248,"twenty":-89.146751,"median":-26.565618,"eighty":-16.991447,"marketCap":4521641084},{"date":"2026-03-27","current":-90.084263,"twenty":-89.449174,"median":-26.639308,"eighty":-17.110068,"marketCap":4531148320}],"updateTime":1774739700468},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2590456673","title":"1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years","url":"https://stock-news.laohu8.com/highlight/detail?id=2590456673","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590456673?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:15","pubTimestamp":1765282500,"startTime":"0","endTime":"0","summary":"Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1 KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202238/0/en/1-in-4-metastatic-breast-cancer-patients-treated-with-Novartis-Kisqali-remain-progression-free-beyond-4-years.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","IE00BN0W2W23.USD","PFS","BK4567","LU2413666699.HKD","BK4581","IE00BN0W2V16.EUR","LU2092937221.SGD","BK4585","A","LU2041044095.USD","LU2229751404.USD","LU2089279066.USD","BK4588","LU1543694498.USD","FUL","LU1721428933.USD","BK4144","LU0347712357.USD","BK4211","BK4590","DDFS","EBC","ET","LU2413666426.HKD","BK4109","OS","IE00BN0W2T93.GBP","LU1165135440.EUR","BK4561","BK4121","BK4097"],"gpt_icon":0},{"id":"2590318860","title":"Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2590318860","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590318860?lang=en_us&edition=fundamental","pubTime":"2025-12-09 15:00","pubTimestamp":1765263600,"startTime":"0","endTime":"0","summary":"Progression free survival (PFS) of 74% at 16 months compares favourably to standard of care PFS of 50% at 11.5 months1 Strong PFS consistent across key subgroups Reaffirms selection of iSCIB1+ and tar","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202069/0/en/Scancell-updated-Phase-2-data-shows-continued-improvement-in-progression-free-survival-with-iSCIB1-in-patients-with-first-line-advanced-melanoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","IE00BD0PCF45.HKD","LU1718418525.SGD","IE00B95QR487.USD","LU0690374961.EUR","MAR","BK4211","BK4588","BK4156","GB00B4LPDJ14.GBP","IE00B45NX917.SGD","BK4585","PFS","IE00B1G9WX41.USD","LU2404859667.USD","OS","GB00B4QBRK32.GBP","BK4142","LU0690374615.EUR","IE00B0T0GQ85.USD","LU2404859741.USD","BK4097"],"gpt_icon":0},{"id":"2590910366","title":"Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590910366","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590910366?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:30","pubTimestamp":1765229400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT),","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201984/0/en/Genmab-Announces-New-Data-from-Phase-1b-2-EPCORE-CLL-1-Highlighting-Potential-of-Epcoritamab-as-Monotherapy-and-in-Combination-for-Patients-with-Richter-Transformation-RT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","PFS","BK4195","BK4161","ORR","IE00B7SZL793.SGD","LU2065731478.USD","IE00B66KJ199.SGD","BK4211","OS","CRS","LU0963586101.USD","ASH","BK4109","BK4187","IE0031619046.USD","LU2463526074.USD","BK4006","BK4097","CR"],"gpt_icon":0},{"id":"2590368866","title":"Why Is Arcellx Stock Surging Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590368866","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590368866?lang=en_us&edition=fundamental","pubTime":"2025-12-09 02:23","pubTimestamp":1765218180,"startTime":"0","endTime":"0","summary":"Arcellx shares updated ASH data showing strong response and survival results for anito-cel in relapsed multiple myeloma, with analysts highlighting its emerging profile.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/08/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/08/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49265004/why-is-arcellx-stock-surging-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49265004/why-is-arcellx-stock-surging-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU1066051498.USD","IE00B7SZLL34.SGD","LU0882574055.USD","BK4550","BK4588","BK4211","OS","LU2463526074.USD","BK4195","BK4109","LU1839511570.USD","LU0058720904.USD","IE00B19Z3B42.SGD","LU1674673428.USD","BK4097","IE00B3T34201.USD","LU0289739699.SGD","PFS","LU2089984988.USD","SG9999015978.USD","SG9999015986.USD","SG9999015945.SGD","IE00B19Z3581.USD","ORR","SG9999015952.SGD","LU0320765992.SGD","LU2324357040.USD","ACLX","IE00BSNM7G36.USD","BK4532","LU2087621335.USD","IE0002270589.USD","BK4566","BK4139","GILD","LU0889565916.HKD","ASH","LU1585245621.USD","LU1674673691.USD","LU1778281490.HKD","LU1430594728.SGD","BK4583","LU0234570918.USD","BK4578","LU0823416689.USD","LU1066053197.SGD","LU1571399168.USD","BK4585","LU0109394709.USD","LU0114720955.EUR"],"gpt_icon":0},{"id":"2589354927","title":"Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589354927","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589354927?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:30","pubTimestamp":1765207800,"startTime":"0","endTime":"0","summary":"Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201702/0/en/Corvus-Pharmaceuticals-Presents-Final-Data-from-Soquelitinib-Phase-1-1b-T-Cell-Lymphoma-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","LU2463526074.USD","ASH","BK4109","OS","CRVS","BK4139","PFS","BK4211","BK4097","BK4568"],"gpt_icon":0},{"id":"2589355106","title":"Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355106","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355106?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:35","pubTimestamp":1765200900,"startTime":"0","endTime":"0","summary":"Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201559/0/en/Autolus-Therapeutics-Presents-Initial-Clinical-Data-in-Pediatric-r-r-B-ALL-Patients-and-Other-Oncology-Data-at-the-American-Society-of-Hematology-ASH-Annual-Meeting-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4117","BK4007","BK4109","LU0985320562.USD","ORR","BK4107","IE00B19Z4B17.USD","CRS","LENZ","UCL","BK4230","IE00B66KJ199.SGD","OS","FC","BK4585","LU0963586101.USD","LU1571399168.USD","BK4161","BK4097","BK4187","BK4006","IE0031619046.USD","LU1699723380.USD","BK4132","CAR","ALL","AFG","LU2355687059.USD","LU2463526074.USD","BK4022","BK4123","LU2065731478.USD","ASH","BK4588","BK4539","IE00B7SZL793.SGD","BK4139","BK4533"],"gpt_icon":0},{"id":"2589533799","title":"Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum","url":"https://stock-news.laohu8.com/highlight/detail?id=2589533799","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589533799?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:50","pubTimestamp":1765194600,"startTime":"0","endTime":"0","summary":"– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute le","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201378/0/en/Syndax-Highlights-Leadership-in-Menin-Inhibition-at-ASH-2025-with-Multiple-Revuforj-revumenib-Presentations-Spanning-the-Acute-Leukemia-Treatment-Continuum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2355687059.USD","OS","ASH","CR","BK4585","BK4107","BK4161","LU1699723380.USD","BK4109","ALL","BK4588","BK4097","LU0985320562.USD","BK4533","BK4129","ORR","LU2463526074.USD","LU1571399168.USD","HSCT","ECG"],"gpt_icon":0},{"id":"2589807890","title":"ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances","url":"https://stock-news.laohu8.com/highlight/detail?id=2589807890","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589807890?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:10","pubTimestamp":1765156200,"startTime":"0","endTime":"0","summary":"Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients80% ORR achieved in newly diag","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201167/0/en/ASH-2025-Ascentage-Pharma-Presents-Encouraging-Data-from-Phase-Ib-II-Study-of-Bcl-2-Inhibitor-Lisaftoclax-in-Venetoclax-Exposed-Patients-with-Myeloid-Malignances.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4203","ORR","OS","BK4097","LU2463526074.USD","AAPG","HR","BK4225","BK4139","ASH","BK4109"],"gpt_icon":0},{"id":"2589802971","title":"RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study","url":"https://stock-news.laohu8.com/highlight/detail?id=2589802971","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589802971?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:00","pubTimestamp":1765155600,"startTime":"0","endTime":"0","summary":"SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinibamong Asian patients.Results from 501 participants who self-identified as Asian in the MARIPOSA trial, showed those treated with amivantamab plus lazertinib had a 26 percent lower risk of death compared with osimertinib , based on a median follow-up of 38.7 months. MedianOSfor the combination was not yet reached compared with 38.4months for osimertinib . Survival projections suggest that amivantamab plus lazertinib could extend median OS to more than a year beyond that achieved with osimertinib. At three years, 61 percent of patients treated with the combination were alive compared with 53 percent of those receiving osimertinib. The survival advantage was maintained at 42 months, with survival rates of 59 percent and 46 percent,respec","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-delivers-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-benefit-for-asian-patients-with-egfr-mutated-non-small-cell-lung-cancer-in-the--302633939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","LU2505996681.GBP","IE00B3T34201.USD","LU0234572021.USD","IE00BLSP4452.SGD","BK4195","BK4550","LU1778281490.HKD","LU2129689514.USD","BK4581","ORR","LU1894683348.USD","OS","LU0466842654.USD","LU1267930813.SGD","LU0203347892.USD","BK4504","BK7095","JNJ","LU0345770308.USD","IE00BGHQF631.EUR","IE00B19Z3581.USD","LU1162221912.USD","LU2505996509.AUD","LU1732799900.SGD","LU0345770993.USD","IE00BJT1NW94.SGD","PFS","IE00B1BXHZ80.USD","LU0058720904.USD","LU2129689431.USD","LU2468319806.SGD","SEER","LU0912757837.SGD","LU0098860793.USD","ORR.AU","IE00B19Z3B42.SGD","LU1929549753.HKD","BK4585","LU2089984988.USD","IE00B4R5TH58.HKD","LU1261432733.SGD","BK4534","LU0345769631.USD","LU1066051225.USD","IE00B3PB1722.GBP","LU1074936037.SGD","LU2602419157.SGD","LU1674673691.USD","LU2592432038.USD"],"gpt_icon":0},{"id":"2589877324","title":"ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877324","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589877324?lang=en_us&edition=fundamental","pubTime":"2025-12-07 21:00","pubTimestamp":1765112400,"startTime":"0","endTime":"0","summary":"- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an appr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201128/0/en/ALX-Oncology-Announces-Positive-Results-from-Ongoing-Investigator-Sponsored-Phase-2-Trial-Evaluating-Evorpacept-in-Combination-with-Standard-of-Care-Treatment-in-Patients-with-Indo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMP","BK4211","BK4097","OS","PR","BK4195","BK4213","ORR","BK4109","CR","ASH","LU2463526074.USD","BK4161","ALX","BK4080","BK4124","BK4231","PFS"],"gpt_icon":0},{"id":"2589782202","title":"TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2589782202","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589782202?lang=en_us&edition=fundamental","pubTime":"2025-12-07 06:30","pubTimestamp":1765060200,"startTime":"0","endTime":"0","summary":"Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up re","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201100/0/en/TScan-Therapeutics-Announces-Positive-Updated-Data-from-the-ALLOHA-Phase-1-Heme-Trial-at-the-67th-American-Society-of-Hematology-Annual-Meeting-and-Exposition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","LENZ","BK4117","LU2463526074.USD","BK4139","OS","BK4107","BK4007","AFG","KOL","BK4097","ASH","BK4539"],"gpt_icon":0},{"id":"2589800824","title":"OneStream (OS): Assessing Valuation After Strategic Leadership Changes and AI-Focused Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2589800824","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589800824?lang=en_us&edition=fundamental","pubTime":"2025-12-07 01:21","pubTimestamp":1765041689,"startTime":"0","endTime":"0","summary":"OneStream (OS) just reshuffled its C suite, elevating AI leader Scott Leshinski to president, promoting Pamela McIntyre to chief accounting officer, and outlining a CFO handoff to board veteran John Kinzer.\nSee our latest analysis for OneStream.\nThe leadership reshuffle comes after a tough stretch in the market, with a year to date share price return of minus 35.03 percent and a one year total shareholder return of minus 40.18 percent, suggesting sentiment has cooled even as management leans...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8042000-choice1-main-header/1585186669041","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8042000-choice1-main-header/1585186669041"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-os/onestream/news/onestream-os-assessing-valuation-after-strategic-leadership","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-os/onestream/news/onestream-os-assessing-valuation-after-strategic-leadership","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4543","BK4588","BK4551","BK4528","AI","OS","BK4023","BK4097","BK4587"],"gpt_icon":0},{"id":"2589261588","title":"Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589261588","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589261588?lang=en_us&edition=fundamental","pubTime":"2025-12-06 22:30","pubTimestamp":1765031400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in pat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201065/0/en/Genmab-Announces-Data-From-Multiple-Clinical-Trials-Showing-Treatment-with-Fixed-Duration-Epcoritamab-Led-to-Remissions-in-First-Line-Diffuse-Large-B-Cell-Lymphoma-DLBCL-and-Follic.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0545562505.USD","IE0031619046.USD","IE00B66KJ199.SGD","LU1228905540.USD","BR","IPI","LU2463526074.USD","BK4109","BK4093","LU1228905037.USD","BK4097","BK4161","CR","BK4588","BK4106","BK4187","LU0963586101.USD","ASH","ORR","BK4211","BK4006","CRS","BK4195","BK4226","LU0390134368.USD","IE0009354923.USD","BK4548","IE0034235188.USD","IE00B7SZL793.SGD","BK4585","PFS","IE00B19Z4B17.USD","OS","LU2065731478.USD"],"gpt_icon":0},{"id":"2589841767","title":"Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2589841767","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589841767?lang=en_us&edition=fundamental","pubTime":"2025-12-06 11:11","pubTimestamp":1764990660,"startTime":"0","endTime":"0","summary":"Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201030/0/en/Toripalimab-Presents-Long-Term-Survival-Benefits-as-1st-line-Treatment-for-Advanced-Nasopharyngeal-Carcinoma-and-Esophageal-Squamous-Cell-Carcinoma-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","ITT","LU0054578231.USD","ORR","BK4006","LU0053671581.USD","LU0757428866.USD","IE0031619046.USD","IE00B19Z4B17.USD","RCC","PFS","BK4157","BK4161","GP","OS","BK4211","AEIS","LU1815336091.USD","BK4195","BK4149","IE00B7SZL793.SGD","BK4097","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2589550638","title":"Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2589550638","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589550638?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:00","pubTimestamp":1764892800,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Dec.  04, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International(NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200415/0/en/Ascentage-Pharma-Announces-Global-Registrational-Phase-III-Study-of-Olverembatinib-in-First-Line-Treatment-of-Ph-ALL-Cleared-by-US-FDA-and-EMA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494708.USD","ASH","IE00B3PB1722.GBP","LU1599440770.SGD","LU0234572021.USD","ALL","LU1066051225.USD","BK4134","BK4020","BK4161","LU1880398471.USD","LU1244550577.SGD","LU1674673428.USD","III","LU0234570918.USD","SG9999015986.USD","AAPG","IE00BFMHRM44.USD","LU1244550221.USD","LU2237443382.USD","LU2506952097.USD","BK4579","BK4139","CR","LU0985320562.USD","IE00BFXG1179.USD","LU1929549753.HKD","LU0868494617.USD","IE00BZ1G4Q59.USD","EMA","LU0348723411.USD","BK4581","BK4585","LU0792757196.USD","LU1894683348.USD","CDE","LU1221951046.USD","LU1571399168.USD","BK4017","LU0203347892.USD","LU1778281490.HKD","LU2286300806.USD","BK4560","BK4525","LU1221951129.SGD","IE00BDGV0183.EUR","IE00BVYPNW00.USD","OS","CSCO"],"gpt_icon":0},{"id":"2589179858","title":"OneStream Director Jonathan D. Mariner Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589179858","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589179858?lang=en_us&edition=fundamental","pubTime":"2025-12-05 06:27","pubTimestamp":1764887263,"startTime":"0","endTime":"0","summary":"Jonathan D. Mariner, Director at OneStream Inc., has reported a disposal of common shares of the company, according to a recent Form 4 filing with the SEC. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OneStream Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL75FbBn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"OneStream Director Jonathan D. Mariner Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2588045492","title":"Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM","url":"https://stock-news.laohu8.com/highlight/detail?id=2588045492","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588045492?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:01","pubTimestamp":1764763260,"startTime":"0","endTime":"0","summary":"Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no n","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3198744/0/en/Black-Diamond-Therapeutics-Announces-Preliminary-Phase-2-Data-for-Silevertinib-in-1L-NSCLC-and-Plans-for-a-Phase-2-Trial-of-Silevertinib-in-GBM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","BK4195","BK4139","OS","PFS","BK4211","BDTX"],"gpt_icon":0},{"id":"2588906696","title":"OneStream Names Scott Leshinski President and Appoints John Kinzer Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2588906696","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588906696?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:05","pubTimestamp":1764709520,"startTime":"0","endTime":"0","summary":"OneStream Inc. has announced several management changes. Scott Leshinski, currently Executive Vice President - AI & Operational Analytics, will become President effective January 1, 2026. CFO Bill Koefoed will step down on December 31, 2025, and John Kinzer, a member of the Board of Directors and former CFO of HubSpot and Blackboard, will become Interim CFO starting January 1, 2026. The company has also created a new Chief Accounting Officer role.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OneStream Inc. published the original content used to generate this news brief via PR Newswire  on December 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL1qfBLh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4613","IE00BMPRXR70.SGD","LU2210149790.SGD","BK4023","IE00B894F039.SGD","OS","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","IE00BZ9MQY76.HKD","IE00BMPRXN33.USD","LU2095319765.USD","LU2210150020.SGD","BK4588","BK4528","BK4097","HUBS","LU2054465674.USD"],"gpt_icon":0},{"id":"2588906066","title":"Onestream Inc - John Kinzer to Join Onestream as Interim CFO January 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588906066","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588906066?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:05","pubTimestamp":1764709500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUAYJZCP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2588669030","title":"Onestream Inc - CFO BILL Koefoed to Depart December 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588669030","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588669030?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:05","pubTimestamp":1764709500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUAYJZCP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4097","OS"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}